Table 4.
Invasive strategy and mortality, NSTEMI patients ≥75 years
| OR (95% CI) | p value | |
|---|---|---|
| Association between an invasive strategy and 30-day mortalitya | ||
| Unadjusted | 0.18 (0.13–0.24) | <0.0001 |
| Age adjusted | 0.23 (0.16–0.32) | <0.0001 |
| Adjusted for baseline characteristicsb | 0.31 (0.21–0.45) | <0.0001 |
| Multivariate adjustedc | 0.39 (0.25–0.60) | <0.0001 |
| HR (95% CI) | p value | |
|---|---|---|
| Long-term mortality in the invasive versus the conservative group for patients surviving the first 30 days (n = 1,805)d | ||
| Unadjusted | 0.29 (0.26–0.33) | <0.0001 |
| Age adjusted | 0.36 (0.31–0.43) | <0.0001 |
| Adjusted for baseline characteristicsb | 0.40 (0.33–0.47) | <0.0001 |
| Multivariate adjustedc | 0.49 (0.41–0.59) | <0.0001 |
a
Logistic regression.
b
Adjustment for baseline characteristics: Age, female gender, s-creatinine, out-of-hospital resuscitation, previous hypertension, -myocardial infarction, –revascularisation or -stroke, diabetes mellitus, peripheral artery disease.
c
Multivariate adjusted: adjustment for baseline characteristics + in-hospital atrial fibrillation/flutter, heart failure, cardiogenic shock, antibiotic treatment.
d
Cox regression with landmark at 30 days; median follow-up 1,155 days (25–75th percentile: 634–1,687).
NSTEMI, non-ST-elevation myocardial infarction; HR, hazard ratio.